Generate Biomedicines, Inc (GENB) insider trading
Every open-market stock purchase and sale by Generate Biomedicines, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders bought $50.3M over the last 12 months (6 buys).
- Last insider buy: Michael Nally (CEO), $240K, 7 months ago.
Last 12 months: insiders bought $50.3M (6 buys) and sold $0 (0 sales). Last close $12.87 on Jun 4, 2026.
Recent GENB insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Mar 4, 2026 | Michael Nally (CEO) | Bought | $240K |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought | $25M |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought | $25M |
| Mar 2, 2026 | Jane L Mendillo (Insider) | Bought | $24K |
| Mar 2, 2026 | Jason Silvers (CFO) | Bought | $16K |
| Mar 2, 2026 | Jason Silvers (CFO) | Bought | $8K |
| Mar 2, 2026 | Beth Grous (C-suite exec) | Bought | $4.8K |
| Mar 2, 2026 | Stephane Bancel (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
| Mar 2, 2026 | Noubar Afeyan (Insider) | Bought (not open market) | — |
Who's trading GENB
- Michael Nally, CEO: bought $240K (1 buy), last Mar 4, 2026
- Jane L Mendillo, Insider: bought $24K (1 buy), last Mar 2, 2026
- Stephane Bancel, Insider: other filings, last Mar 2, 2026
- Jason Silvers, CFO: bought $24K (2 buys), last Mar 2, 2026
- Beth Grous, C-suite exec: bought $4.8K (1 buy), last Mar 2, 2026
- Noubar Afeyan, Insider: bought $50M (2 buys), last Mar 2, 2026
- Paul Gray Parker, Insider: other filings, last Feb 26, 2026
- Nancy A Simonian, Insider: other filings, last Feb 26, 2026
- Rupert Vessey, Insider: other filings, last Feb 26, 2026
- Frances Arnold, Insider: other filings, last Feb 26, 2026
- Marsha Fanucci, Insider: other filings, last Feb 26, 2026
- Gevorg Grigoryan, CTO: other filings, last Feb 26, 2026
- Laurie Anne Lee, C-suite exec: other filings, last Feb 26, 2026
- Sean Martin, C-suite exec: other filings, last Feb 26, 2026
Get free alerts when an insider at Generate Biomedicines, Inc files a new trade →